Remibrutinib

瑞米布替尼

Report date: 2026/05/21 20:00:22
NME

Base Information

Drug NameRemibrutinib
Drug Alias NameRhapsido瑞普多LOU-064LOU064-NXANVP-LOU064-NXA
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsInflammationDisease SusceptibilityPeanut Hypersensitivity +[15] 
Global Approved IndicationsChronic UrticariaUrticaria
Approved Indications in ChinaChronic Urticaria
Original Approved Country/TerritoryUnited States
Original Approved Date2025/09/30
Country/TerritoryCzechiaBelgiumBulgaria +[57] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Schweiz AgNovartis Pharma AgNovartis Europharm Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsInflammationPeanut HypersensitivityAutoimmune Diseases +[10] 
Inactive IndicationsDisease SusceptibilityDermatitisSjogren-Larsson Syndrome +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG